{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:55:49Z","timestamp":1794333349291,"version":"4.9.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.urolonc.2022.10.009","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T10:07:55Z","timestamp":1668161275000},"page":"219-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-167X","authenticated-orcid":false,"given":"Philipp","family":"Maisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florestan","family":"Koll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bolenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.-H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian C.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2022.10.009_bib0001","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.10.009_bib0002","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.10.009_bib0003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semradonc.2019.12.005","article-title":"The impact of radiation therapy on innate and adaptive tumor immunity","volume":"30","author":"Brandmaier","year":"2020","journal-title":"Semin Radiat Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.10.009_bib0004","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: Changing the game in immunotherapy","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2022.10.009_bib0005","first-page":"e4103","article-title":"Abscopal Effect of radiotherapy in the immunotherapy era: Systematic review of reported cases","volume":"11","author":"Dagoglu","year":"2019","journal-title":"Cureus"},{"issue":"1076","key":"10.1016\/j.urolonc.2022.10.009_bib0006","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170157","article-title":"Combining radiotherapy with immunotherapy: The past, the present and the future","volume":"90","author":"Van Limbergen","year":"2017","journal-title":"Br J Radiol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.10.009_bib0007","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nature Rev Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2022.10.009_bib0008","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.currproblcancer.2015.10.001","article-title":"Systematic review of case reports on the abscopal effect","volume":"40","author":"Abuodeh","year":"2016","journal-title":"Curr Probl Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2022.10.009_bib0009","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","article-title":"Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity","volume":"180","author":"Lugade","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.10.009_bib0010","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.urolonc.2022.10.009_bib0011","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.urolonc.2022.10.009_bib0012","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.10.009_bib0013","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/cam4.3718","article-title":"Safety and Efficacy of PD-1\/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: A systematic review and meta-analysis","volume":"10","author":"Geng","year":"2021","journal-title":"Cancer Med"},{"issue":"15","key":"10.1016\/j.urolonc.2022.10.009_bib0014","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2022.10.009_bib0015","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 1.1. AWMF-Registrierungsnummer 032\/038OL 2016."},{"issue":"7","key":"10.1016\/j.urolonc.2022.10.009_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"19","key":"10.1016\/j.urolonc.2022.10.009_bib0017","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.urolonc.2022.10.009_bib0018","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41391-020-0254-y","article-title":"Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: Safety, feasibility, and exploratory analysis","volume":"24","author":"Yuan","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"10.1016\/j.urolonc.2022.10.009_bib0019","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.10.009_bib0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2021.08.011","article-title":"Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: The phase 2 ICE-PAC clinical trial","volume":"81","author":"Kwan","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.10.009_bib0021","doi-asserted-by":"crossref","first-page":"S1442","DOI":"10.1016\/j.annonc.2022.08.081","volume":"33","author":"Schmid","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.10.009_bib0022","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1200\/JCO.2021.39.6_suppl.428","article-title":"INTACT (S\/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients","volume":"39","author":"Singh","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.485","article-title":"Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)","volume":"38","author":"Weickhardt","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4504","article-title":"Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial","volume":"39","author":"Balar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4531","article-title":"Safety evaluation of combined PD-1+CTLA4 inhibition concurrently to chemoradiotherapy (CRT) in localized muscle invasive bladder carcinoma (MIBC)","volume":"39","author":"de Ruiter","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.10.009_bib0026","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2018.04.070","article-title":"Dose-limiting urinary toxicity with Pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer","volume":"101","author":"Tree","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2022.10.009_bib0027","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1016\/j.annonc.2020.08.848","article-title":"776P Phase II trial of concurrent nivolumab in urothelial bladder cancer with radiation therapy in localized\/locally advanced disease for chemotherapy ineligible patients [NUTRA trial]","volume":"31","author":"Vaishampayan","year":"2020","journal-title":"Ann Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0028","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.398","article-title":"Phase II clinical study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results for primary analyses and survival. BTCRC-GU15-023","volume":"39","author":"Joshi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0029","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.517","article-title":"Safety lead-in of phase II SBRT and durvalumab with or without tremelimumab for unresectable and cisplatin-ineligible, locally advanced or metastatic bladder cancer","volume":"40","author":"Kundu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2022.10.009_bib0030","unstructured":"Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer - Full Text View - ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03617913. Accessed 20, July 2022."},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4505","article-title":"Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial","volume":"39","author":"Garcia del Muro","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.10.009_bib0032","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2020.12.033","article-title":"Phase 1 Trial of Atezolizumab Plus Trimodal therapy in patients with localized muscle-invasive bladder cancer","volume":"110","author":"Marcq","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2022.10.009_bib0033","unstructured":"Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma - Full Text View - ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03287050. Accessed 20, July 2022."},{"issue":"5","key":"10.1016\/j.urolonc.2022.10.009_bib0034","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","article-title":"Randomized Phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma","volume":"75","author":"Sundahl","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.10.009_bib0035","article-title":"Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study","volume":"38","author":"Masini","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2022.10.009_bib0036","unstructured":"A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients - Full Text View - ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02599779. Accessed 20, July 2022."},{"issue":"2","key":"10.1016\/j.urolonc.2022.10.009_bib0037","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/COC.0000000000000636","article-title":"A pilot study of radiation therapy in combination with pembrolizumab in patients with metastatic renal cell cancer","volume":"43","author":"Lin","year":"2020","journal-title":"Am J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0038","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.277","article-title":"Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial","volume":"39","author":"Siva","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0039","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.614","article-title":"Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC)","volume":"38","author":"Hammers","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.10.009_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000535","article-title":"Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: A prospective multicentre study","volume":"4","author":"Dengina","year":"2019","journal-title":"ESMO Open"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0041","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.003","article-title":"Clinical results of PERICLES: A phase II trial investigating atezolizumab +\/- radiotherapy for advanced squamous cell carcinoma of the penis","volume":"40","author":"de Vries","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.10.009_bib0042","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bju.15284","article-title":"Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma","volume":"127","author":"Kroeze","year":"2021","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.urolonc.2022.10.009_bib0043","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s12094-022-02844-5","article-title":"Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: A preliminary, multicentre experience","volume":"24","author":"Francolini","year":"2022","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.10.009_bib0044","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","article-title":"Multicenter evaluation of the tolerability of combined treatment With PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy","volume":"98","author":"Bang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.5_suppl.39","article-title":"Multi-institutional report on toxicities from combined radiation and nivolumab","volume":"36","author":"Parker","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0046","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5088","article-title":"Prostate cancer with oligometastatic relapse: Combining stereotactic ablative radiotherapy and durvalumab, a randomized phase II trial (POSTCARD - GETUG-P13)","volume":"37","author":"Supiot","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2022.10.009_bib0047","doi-asserted-by":"crossref","first-page":"S672","DOI":"10.1016\/j.annonc.2021.08.1157","article-title":"644TiP SAABR: Single arm phase II study of abiraterone\u202f+\u202fatezolizumab\u202f+\u202fGnRH analog and stereotactic body radiotherapy (SBRT) to the prostate in men with newly diagnosed hormone-sensitive metastatic prostate cancer (mHSPC)","volume":"32","author":"Rathkopf","year":"2021","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0048","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS500","article-title":"EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE)\u2014An ECOG-ACRIN and NRG Collaboration","volume":"39","author":"Joshi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0049","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS605","article-title":"NEXT: A phase II, open-label study of nivolumab adjuvant to chemoradiation in patients (pts) with localized muscle invasive bladder cancer","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.10.009_bib0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12885-019-6503-6","article-title":"Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT)","volume":"20","author":"Schmid","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2022.10.009_bib0051","article-title":"INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer-SWOG\/NRG1806","volume":"38","author":"Singh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0052","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5093","article-title":"Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992","volume":"38","author":"Balar","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.10.009_bib0053","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s12885-021-08088-w","article-title":"Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): Study protocol for a phase 2, open-label, randomized controlled trial","volume":"21","author":"Spaas","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2022.10.009_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2021.12.019","article-title":"RE-ARMing the immune response to bladder cancer with radiotherapy","author":"Wilkins","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"6","key":"10.1016\/j.urolonc.2022.10.009_bib0055","article-title":"Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab\/nivolumab for metastatic kidney cancer (CYTOSHRINK)","volume":"38","author":"Lalani","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0056","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.86","article-title":"ICEPAC: A phase II multicenter study of avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC)","volume":"39","author":"Azad","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2022.10.009_bib0057","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e16058","article-title":"An exploratory study to investigate the immunomodulatory activity of radiation therapy in combination with pembrolizumab in patients with renal cell cancer","volume":"35","author":"Lin","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392200388X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392200388X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:27:17Z","timestamp":1761042437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392200388X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S107814392200388X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}